Coeptis Therapeutics Hldgs I
13F holders, Q1 2025 (March 31)9holders +4
4new positions
0sold out
$9.37avg. 13F price*
At the end of Q1 2025, 9 institutions reported holding Coeptis Therapeutics Hldgs I in their 13F filings, up 4 from Q4 2024. 4 opened new positions and 0 sold out. The largest holders were Vanguard Group Inc. ($229K), Geode Capital Management, LLC ($187K) and UBS Group AG ($81K).
- Company
- Coeptis Therapeutics Hldgs I
- CUSIP
- 19207A207
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $421K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 46,786 shares bought and 48 shares sold, net +46,738 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Vanguard Group Inc. | 0.00% | New | 24,437 | $229K |
| Geode Capital Management, LLC | 0.00% | New | 19,969 | $187K |
| UBS Group AG | 0.00% | Add +27.6% | 8,635 | $81K |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 1,000 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -6.6% | 675 | $6K |
| Osaic Holdings, Inc. | 0.00% | New | 500 | $5K |
| Bank of America Corp. | 0.00% | Add +63.6% | 18 | $169 |
| Semmax Financial Advisors Inc. | 0.00% | No change | 5 | $48 |
| Barclays PLC | 0.00% | New | 3 | $28 |
"% of holder's portfolio" is COEPTIS THERAPEUTICS HLDGS I's weight in each manager's 13F, not the share of Coeptis Therapeutics Hldgs I the manager owns.